Why did Becton Dickinson (BDX) stock move recently?

On 7/28/2026, Becton Dickinson moved +4.7% — Becton Dickinson shares rose after UBS initiated coverage with a Buy rating and $190 price target on July 28. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Becton Dickinson (BDX) overvalued or fairly valued?

MarketChacha shows Becton Dickinson's valuation in context — a trailing P/E of about 50.6, a forward P/E of about 13.7, a price-to-book of about 2.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Becton Dickinson's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (2.11×) from reported figures — education, not a rating.

What is Becton Dickinson's revenue?

Becton Dickinson reported revenue of $21.8B for FY2025, with net profit of $1.7B, per official filings.

What is the share price of Becton Dickinson (BDX)?

Becton Dickinson last traded at $182.09 (+0.1% on the day), as of 8/17/2026 — a delayed quote shown for education, not investment advice.

Becton Dickinson

BDX · NYSE · Healthcare · United States

Snapshot

TickerBDX

ExchangeNYSE

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryUnited States

Employees72,000

HeadquartersFranklin Lakes, United States

Websitewww.bd.com

Filings tracked25

About Becton Dickinson

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Who owns it

Insiders0.4%
Institutions99.5%
Public & other0.0%

1,917 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.93%
Vanguard Capital Management LLC6.53%
State Street Corporation5.44%
Vanguard Portfolio Management LLC5.43%
First Eagle Investment Management, LLC5.01%
Invesco Ltd.3.69%
Massachusetts Financial Services Co.3.14%
Geode Capital Management, LLC2.95%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of 6.6% is on the low side — the business earns a modest return on shareholder capital.

Cash conversion2.11×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend7.7% → 7.7%

Margin has held broadly steady over the period — stable profitability.

Return on equity6.6%

Latest ROE of 6.6% is on the low side — the business earns a modest return on shareholder capital.

Growth qualityrev 6% · PAT 6%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $4.6B · EPS 2.73

Est. earnings growth -6.2%

Next fiscal year

Rev $19.7B · EPS 13.31

Est. earnings growth +5.4%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$21.8B

Net margin

7.7%

ROE

6.6%

Revenue CAGR (2y)

+6.2%

Profit CAGR (2y)

+6.3%

EPS (FY2025)

5.82

Net profit (FY2025)

$1.7B

Ask MarketChacha about BDX

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 28, 2026
Becton Dickinson shares rose after UBS initiated coverage with a Buy rating and $190 price target on July 28.
source 1 ↗source 2 ↗· confidence: high
Jul 27, 2026
No clear company-specific catalyst identified in recent filings or credible news coverage; the move appears to reflect broader market or sector sentiment amid ongoing institutional buying interest.
source 1 ↗source 2 ↗· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$21.8B	$1.7B	5.82	7.7%	6.6%
FY2024	$20.2B	$1.7B	5.86	8.4%	6.6%
FY2023	$19.4B	$1.5B	4.94	7.7%	5.8%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$5.0B	$377.0M	1.37	7.6%
2026Q1	$4.7B	$-311.0M	-1.11	-6.6%
2025Q4	$5.3B	$382.0M	1.34	7.3%
2025Q2	$4.7B	$574.0M	2.00	12.1%
2025Q1	$4.5B	$308.0M	1.07	6.9%
2024Q4	$5.2B	$303.0M	1.04	5.9%
2024Q2	$5.0B	$487.0M	1.68	9.8%
2024Q1	$5.0B	$537.0M	1.85	10.6%
2023Q4	$4.7B	$281.0M	0.96	6.0%
2023Q2	$4.9B	$407.0M	1.36	8.3%
2023Q1	$4.8B	$460.0M	1.53	9.5%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC8/6/2026material
10-Q filing
SEC8/6/2026
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC7/22/2026material
8-K — Reg FD disclosure
SEC5/29/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC5/20/2026material
8-K — Other events, Exhibits
SEC5/12/2026material
8-K — Results of operations, Exhibits
SEC5/7/2026material
8-K/A — Executive/director change, Reg FD disclosure, Exhibits
SEC5/7/2026
10-Q filing
SEC5/7/2026
8-K — Bylaw/charter change, Exhibits
SEC4/29/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC4/9/2026material
8-K — Results of operations, Exhibits
SEC4/2/2026material
8-K — Other events, Exhibits
SEC2/25/2026material
8-K — Other events, Exhibits
SEC2/10/2026material
8-K — Results of operations, Exhibits
SEC2/9/2026material
8-K — Material agreement, Executive/director change, Reg FD disclosure, Other events, Exhibits
SEC2/9/2026material
10-Q filing
SEC2/9/2026
8-K — Reg FD disclosure, Exhibits
SEC2/5/2026material
8-K — Unregistered equity sale, Bylaw/charter change, Exhibits
SEC2/5/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC1/30/2026material
8-K filing
SEC1/6/2026material

2025

8-K/A — Executive/director change, Exhibits
SEC12/1/2025
10-K filing
SEC11/25/2025
8-K — Executive/director change, Exhibits
SEC11/17/2025material
8-K — Results of operations, Exhibits
SEC11/6/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.